Precision System Science, Co., Ltd (PSS) announced today that PSS and Nordiag ASA (Oslo, Norway) have entered into basic development agreement of reagents for next generation sequencer, development of such reagents protocols for SX-8G Compact and the distribution of the reagents by both companies.

The genetic analysis market, using next generation sequencer, is currently $1 billion USD and is estimated to reach $4 billion in 2015. As sample preparation before next generation sequencer is generally performed manually, automating the process is highly demanded for further spread of such analysis. Thus, PSS has started marketing of SX-8G Compact, an automatic sample preparation instrument for next generation sequencer in collaboration with IntegenX Inc. SX-8G Compact, which originally was developed as a DNA extraction device using PSS’s patented Magtration? Technology, is well suited to expand the market for automation of next generation sequencing library preparation, demonstrating its multi-purpose capability.

According to the agreement, Nordiag ASA develops on the behalf of PSS reagents for next generation sequencer, development of such reagents protocols for SX-8G Compact. After validated by the third party institutions, PSS should apply the reagents and protocols to SX-8G Compact. PSS, through the development consignment to Nordiag ASA, has entered into reagents market along with the instrument of sample preparation for next generation sequencer, seeking further use of genetic analysis.

About Precision System Science, Co., Ltd. (PSS):

PSS, located at Matsudo, Japan, is a leading global provider of Laboratory instruments for nucleic acid extraction. The company specializes in the development and production of automated instruments. As an original equipment manufacturer, PSS is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded as a maintenance and service company for clinical laboratory instruments in 1985, the company has manufacturing, research and development sites in Japan and maintains a sales and service network in the US and Europe. In the fiscal year ended June 30, 2010, PSS generated sales of 5.6 billion JP YEN. Registered shares of PSS are traded on the JASDAQ ticker code 7707.

For more information please visit www.pss.co.jp.

About NorDiag:

NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company’s sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 40 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.

For further information – www.nordiag.com.